CATX Jonathan Robert Hunt buys $50K worth of shares
Nov 28, 2024, 5:33 AM
-24.37%
What does CATX do
Perspective Therapeutics, based in Seattle, is a biotechnology company focused on developing radiopharmaceuticals for cancer treatment using the alpha-emitting isotope 212Pb. Their programs for melanoma and neuroendocrine tumors are in Phase I/IIa trials.
Jonathan Robert Hunt bought 12,829 shares of CATX on 25 November at $3.88 per share, worth a total of $50K. They now own 48,800 CATX shares, or a 36% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
